IGM Biosciences Inc - Asset Resilience Ratio
IGM Biosciences Inc (IGMS) has an Asset Resilience Ratio of 68.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check IGMS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how IGM Biosciences Inc's Asset Resilience Ratio has changed over time. See IGMS equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down IGM Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IGMS company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $73.66 Million | 68.84% |
| Total Liquid Assets | $73.66 Million | 68.84% |
Asset Resilience Insights
- Very High Liquidity: IGM Biosciences Inc maintains exceptional liquid asset reserves at 68.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
IGM Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare IGM Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for IGM Biosciences Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for IGM Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 59.20% | $157.29 Million | $265.71 Million | +6.02pp |
| 2023-12-31 | 53.18% | $225.16 Million | $423.41 Million | -6.40pp |
| 2022-12-31 | 59.58% | $305.93 Million | $513.50 Million | +27.31pp |
| 2021-12-31 | 32.27% | $96.21 Million | $298.13 Million | +1.63pp |
| 2020-12-31 | 30.64% | $125.19 Million | $408.63 Million | -41.58pp |
| 2019-12-31 | 72.22% | $188.74 Million | $261.35 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $3.98 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $1.39 Million | -- |
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more